CSIMarket
 
Adagio Medical Holdings inc   (NASDAQ: ADGM)
 

Adagio Medical Holdings Inc's Customers Performance

ADGM



 
ADGM's Source of Revenues

List of ADGM Customers




for the same period Adagio Medical Holdings Inc

List of ADGM Customers





Adagio Medical Holdings Inc's Comment on Sales, Marketing and Customers



The company operates in the electrophysiology (EP) device market, specializing in ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT). Its next-generation catheter is designed to integrate with existing ablation laboratory workflows and functions at lower ablation temperatures. The company has developed Pulsed Field Cryoablation (PFCA) technology, which has been evaluated in the European PARALELL trial for patients with persistent AF and in preclinical studies targeting VT ablations. The global EP device market was valued at approximately $14 billion in 2025, with growth driven by increased procedure volumes and the adoption of pulsed field ablation for AF. The VT market is smaller and underpenetrated, comprising patients with structural heart disease and idiopathic VT, including premature ventricular contractions (PVC). First-line treatments for structural-related VT include anti-arrhythmic drugs and implantable cardioverter defibrillators (ICDs).





Adagio Medical Holdings Inc’s Comment on Sales, Marketing and Customers


The company operates in the electrophysiology (EP) device market, specializing in ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT). Its next-generation catheter is designed to integrate with existing ablation laboratory workflows and functions at lower ablation temperatures. The company has developed Pulsed Field Cryoablation (PFCA) technology, which has been evaluated in the European PARALELL trial for patients with persistent AF and in preclinical studies targeting VT ablations. The global EP device market was valued at approximately $14 billion in 2025, with growth driven by increased procedure volumes and the adoption of pulsed field ablation for AF. The VT market is smaller and underpenetrated, comprising patients with structural heart disease and idiopathic VT, including premature ventricular contractions (PVC). First-line treatments for structural-related VT include anti-arrhythmic drugs and implantable cardioverter defibrillators (ICDs).








ADGM's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Adagio Medical Holdings inc 10.73 0.00 -2.05 41
SUBTOTAL 0.00 0.00 0.00 -

Sources: Adagio Medical Holdings inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Adagio Medical Holdings inc’s corporate clients.
For your research, we’ve provided 9 tables on Adagio Medical Holdings inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.